RxDoctor Payments Data

Katherine Morgan, MD

Surgery · Charleston, SCNPI 1760596241

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.5%), education and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Medical Device Business Services, Inc. at 57.5% of the total. Reporting peaked in 2020 at $7,208 and has fallen 97.6% since, to $172 in 2025.

$12,295in general payments, 2019–2025

Across 25 payments — averaging $491.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$7K
  • Intuitive Surgical$4K
  • Johnson & Johnson$245
  • AbbVie$217
  • Angiodynamics, Inc.$211
  • Impulse Dynamics (USA) Inc.$143
  • plus $266 from 3 others
$16,490in research payments, 2019–2025

Across 2 payments — averaging $8245.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$16K

What the payments were for

  • Consulting fees$7,07058%
  • Travel & lodging$1,0078%
  • Food & beverage$1,21910%
  • Education$3,00024%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,295 in reported general payments places this provider in the 85th percentile of 553 surgery providers in South Carolina.

See all surgery providers in South Carolina

Medicare billing

Part B allowed, 2024
$133,952
Medicare patients
171
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase22$81,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$217$81,79722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 553 surgery providers in South Carolina.

Other surgery in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →